Cardiopulmonary
Pulmonary hypertension (PH)
We understand the ways in which pulmonary hypertension (PH) can impair daily life, and are committed to helping to improve understanding and speedy diagnoses of this group of conditions within the medical profession. We are here to help those affected by PH to lead a full life and receive optimal treatment at the right time.
Understanding pulmonary hypertension
PH is a serious and progressive disease with various causes and no cure. [1], [2]
There are five groups of PH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1]
Our focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.[1]
There are five groups of PH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1]
Our focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.[1]
Our goal is to give people with PH a full life
At Johnson & Johnson, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a full life. We are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.
We want to use our full range of resources to tackle PH. From investment in research and development of new therapies to innovation in medical devices and screening solutions, our commitment to improving outcomes end-to-end along patient pathways is real. We’re focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.
We want to use our full range of resources to tackle PH. From investment in research and development of new therapies to innovation in medical devices and screening solutions, our commitment to improving outcomes end-to-end along patient pathways is real. We’re focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.
Our work is defined by our patient pledge: ‘With You Until PH Isn’t’
We want to:
- Drive early identification and diagnosis of PH; developing educational and screening solutions to speed up referrals to specialist centres
- Maximise the clinical benefits of our current medicines
- Build an innovative drug development future that focuses on new ways to tackle PH
- Provide holistic support for those affected by PAH, to improve overall wellbeing and quality of life
References
1. Humbert M, et al 2022 ESC/ERS Guidelines for the diagnosis and treatments of pulmonary hypertension. Eur Heart J 2022; 43(38):3618-3731
2. Pulmonary Hypertension Association. About PH. Available at https://phassociation.org/patients/aboutph/ Accessed October 2024